Upon joining the study, the participant will be randomly assigned to one of two groups. One group will receive the medication retifanlimab along with carboplatin and paclitaxel, while the other group will receive a placebo with carboplatin and paclitaxel.

The study is double-blind, meaning neither the participant nor the researchers will know which group the participant is in.

The medications retifanlimab, carboplatin, and paclitaxel are administered through an intravenous infusion. This means the medication is given directly into a vein.

The dosage and frequency of administration will be determined by the study protocol and the healthcare team overseeing the trial.

Throughout the trial, regular monitoring and assessments will be conducted to evaluate the participant’s health and the effectiveness of the treatment.

These assessments may include physical exams, blood tests, and imaging studies to track the progression of the disease.

The treatment phase will continue as per the study protocol until the participant completes the required number of cycles or until the study’s end date, estimated to be February 24, 2025.

Participants will be informed about the next steps and any follow-up care needed after completing the treatment phase.

After the treatment phase, follow-up visits may be scheduled to monitor the participant’s long-term health and any potential side effects.

These visits are important to ensure the participant’s well-being and to gather additional data for the study.